생화학분자생물학회입니다.
AcrAB-TolC, a major efflux pump in Gram negative bacteria: toward understanding its operation mechanism
작성자
Soojin Jang작성일자
2023-07-20조회수
1442Name: Soojin Jang ( soojin.jang@ip-korea.org ) | ||
2014-present | Team leader, Antibacterial Resistance Laboratory, Institut Pasteur Korea | |
2013-2014 | Postdoctoral research fellow, Antibacterial Drug Discovery program, Institut Pasteur Korea | |
2010-2013 | Postdoctoral research fellow, Washington University in St. Louis School of Medicine | |
2003-2010 | Ph.D., Department of Microbiology, Univ. of Illinois at Chicago, USA |
AcrAB-TolC, a major efflux pump in Gram negative bacteria: toward understanding its operation mechanism
Antibiotic resistance (AR) is a silent pandemic that kills millions around world. Although development of new therapeutic agents against antibiotic resistance is in urgent demand, there has been a great challenge especially for Gram negative bacteria that have inherent drug-resistance mediated by impermeable outer membranes and multidrug efflux pumps that actively extrude various drugs from the bacteria. For the last two decades, multidrug efflux pumps including AcrAB-TolC, the most clinically important efflux pump in Gram negative bacteria, have drawn great attention as a strategic target for re-sensitizing bacteria to the existing antibiotics. This article aims to provide a concise overview of AcrAB-TolC operation mechanism reviewing its substrate specificity and recent development of AcrAB-TolC inhibitors. .
BMB Rep. 2023 Jun;56(6):326-334. doi: 10.5483/BMBRep.2023-0070.
https://pubmed.ncbi.nlm.nih.gov/37254571/